Healthcare Realty Trust Incorporated
HR
$20.02
-2.34%
Healthcare Realty Trust Incorporated is a real estate investment trust (REIT) focused on owning, leasing, and managing outpatient medical facilities and other healthcare properties across the United States. The company operates as a specialized niche player within the healthcare real estate sector, concentrating on outpatient assets that are integral to hospital operations, which provides a degree of defensive positioning tied to essential healthcare services. The current investor narrative centers on the stock's significant recovery and outperformance relative to the broader market, driven by a rebound in the healthcare real estate sector and investor search for stable, income-generating assets in a potentially volatile environment, as evidenced by its strong year-to-date and one-year price appreciation.…
HR
Healthcare Realty Trust Incorporated
$20.02
Investment Opinion: Should I buy HR Today?
Rating & Thesis: HR is a Hold. The stock presents a compelling technical and sector story but carries significant fundamental execution risk at its current valuation, with insufficient analyst consensus to provide conviction. The core thesis is that the market is pricing in a successful profitability turnaround that is not yet proven.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The stock trades at a premium P/S of 5.02x despite negative earnings, 2) It has shown remarkable relative strength, outperforming the SPY by 15.97% over the past year, 3) The balance sheet is stable with a debt-to-equity of 0.90, and 4) A single analyst projects a positive EPS of $0.11, offering a potential catalyst. However, the negative trailing P/E of -24.1x and ROE of -5.33% underscore the fundamental challenges.
Risks & Conditions: The biggest risks are the failure to achieve profitability and a re-rating of its sales multiple. This Hold would upgrade to a Buy if the company reports consecutive quarters of positive EPS, confirming the turnaround and supporting its valuation. It would downgrade to a Sell if revenue growth stalls or the net margin fails to improve, triggering a breakdown below key technical support at $19.50. Relative to its own fundamentals, the stock appears overvalued, but it may be fairly valued relative to sector-specific growth expectations that have yet to be realized.
Sign up to view all
HR 12-Month Price Forecast
The outlook for HR is balanced with a tilt towards caution. The stock's dramatic run-up appears to discount much of the anticipated positive news, particularly the shift to profitability. The base case of range-bound consolidation is most likely as the market waits for proof. The AI stance is Neutral due to the high valuation reliance on unproven future earnings versus the compelling technical and defensive sector trends. Confidence is Medium due to the lack of robust analyst coverage and clear historical valuation benchmarks. The stance would upgrade to Bullish on confirmation of sustained positive EPS and expansion of analyst coverage. It would downgrade to Bearish on a breakdown below the $19.50 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Healthcare Realty Trust Incorporated's 12-month outlook, with a consensus price target around $26.03 and implied upside of +30.0% versus the current price.
Average Target
$26.03
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$16 - $26
Analyst target range
Analyst coverage for Healthcare Realty Trust is extremely limited, with data indicating only one analyst providing estimates, which constitutes insufficient coverage for deriving a meaningful consensus price target or recommendation. The implications of this minimal coverage are significant: it typically indicates the stock is a mid-cap ($5.93B market cap) name with limited institutional research focus, which can lead to higher volatility, less efficient price discovery, and potential mispricing opportunities for investors who conduct their own deep due diligence. The single analyst's estimates project an average EPS of $0.11 for the coming period, but without a range of price targets or ratings, the signal strength regarding future expectations is virtually non-existent, placing greater onus on investors to independently assess the company's fundamentals and sector outlook.
Bulls vs Bears: HR Investment Factors
The bull case for HR is anchored in its powerful technical momentum, defensive sector positioning, and anticipated profitability turnaround. The bear case highlights its current lack of earnings, elevated sales-based valuation, and thin analyst coverage. Currently, the bullish evidence appears stronger, driven by the stock's undeniable price trend and low-volatility outperformance in a sought-after sector. The single most important tension in the investment debate is the valuation disconnect: the market is applying a premium P/S multiple of 5.02x to a company that is not yet profitable. The thesis hinges entirely on whether the analyst's projected EPS of $0.11 materializes, justifying the current price, or if profitability remains elusive, leading to a painful multiple compression.
Bullish
- Powerful Technical Uptrend: HR has demonstrated exceptional price momentum, appreciating 38.83% over the past year and 15.13% over the last three months, significantly outperforming the SPY by 15.97 and 3.13 percentage points, respectively. This sustained uptrend, with the stock trading at 99% of its 52-week range near $20.90, signals strong investor conviction and sector rotation into defensive, income-generating assets.
- Defensive Sector & Low Volatility: The company operates in the essential healthcare real estate sector, providing a defensive revenue stream tied to outpatient medical facilities. This is reflected in a beta of 0.827, indicating the stock has been 17% less volatile than the market despite its significant gains, suggesting moves are driven by fundamental or sector-specific catalysts rather than speculative frenzy.
- Strong Balance Sheet & Liquidity: HR maintains a manageable debt-to-equity ratio of 0.90, which is reasonable for a REIT, and exhibits strong liquidity with a current ratio of 1.75. This financial stability provides a buffer against rising interest rates and supports the company's ability to manage its portfolio and potential acquisitions.
- Positive Operating Margin: Despite a negative net margin of -20.84%, the core property operations are profitable, as evidenced by a positive operating margin of 8.04%. This suggests the net loss is likely driven by non-cash accounting items like depreciation and interest, which are standard for REITs, rather than operational failure.
Bearish
- Lack of Profitability & Negative ROE: The company is currently unprofitable, with trailing EPS of -$0.04 and a net margin of -20.84%. This is compounded by a negative Return on Equity (ROE) of -5.33%, indicating the company is not generating positive returns for shareholders on its equity base.
- Elevated Valuation on Sales: With negative earnings, valuation relies on sales multiples. The P/S ratio of 5.02x and EV/Sales of 9.88x appear elevated, though a direct peer comparison is unavailable. The market is valuing the revenue stream highly despite the lack of bottom-line profitability, creating valuation risk if growth stalls.
- Extremely Limited Analyst Coverage: HR has only one analyst providing estimates, indicating minimal institutional research focus for a $5.93B market cap company. This can lead to less efficient price discovery, higher volatility, and increased reliance on investor due diligence, amplifying the impact of any single data point or news event.
- Technical Overextension Near All-Time High: Trading at $20.70 places the stock just 1% below its 52-week high of $20.90, suggesting limited near-term upside before encountering major resistance. A failure to break through this level could trigger a pullback, with potential support around the recent consolidation zone near $19.50.
HR Technical Analysis
The stock is in a sustained and powerful uptrend, having appreciated 38.83% over the past year and 15.13% over the last three months. With a current price of $20.70, it is trading near the top of its 52-week range, approximately 99% of the distance from its 52-week low of $14.69 to its high of $20.90; this positioning near all-time highs signals strong bullish momentum but also raises questions about potential overextension and limited near-term upside before encountering major resistance. Recent momentum shows acceleration, with a 1-month gain of 1.62% building upon the longer-term trend, though this short-term move is less pronounced than the 3-month surge, indicating a potential consolidation phase; the stock has demonstrated significant relative strength, outperforming the SPY by 15.97 percentage points over the past year and 3.13 points over the last three months. Key technical support is anchored at the 52-week low of $14.69, while immediate overhead resistance sits at the 52-week high of $20.90; a decisive breakout above $20.90 would signal a continuation of the bull trend, whereas a failure could lead to a pullback towards recent consolidation levels around $19.50. The stock's beta of 0.827 indicates it has been approximately 17% less volatile than the broader market, which is notable given its substantial price gains and suggests the moves have been driven by sustained fundamental or sector-specific catalysts rather than speculative frenzy.
Beta
0.83
0.83x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$15-$21
Price range past year
Annual Return
+34.2%
Cumulative gain past year
| Period | HR Return | S&P 500 |
|---|---|---|
| 1m | -1.9% | +0.3% |
| 3m | +11.5% | +12.3% |
| 6m | +18.8% | +8.9% |
| 1y | +34.2% | +24.0% |
| ytd | +18.1% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HR Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate figures are not available in the provided dataset; however, analyst estimates point to expected annual revenue of approximately $1.17 billion, but without historical comparatives, the trend of acceleration or deceleration cannot be definitively assessed. The company's profitability is challenged, reporting a trailing net loss as reflected in negative EPS of -$0.04 and a net margin of -20.84%; notably, the operating margin is positive at 8.04%, indicating core property operations are profitable, but overall results are likely burdened by non-cash items like depreciation or interest expenses common to REITs. The balance sheet appears reasonably leveraged with a debt-to-equity ratio of 0.90, which is manageable for a REIT, and strong liquidity is evidenced by a current ratio of 1.75; however, key cash flow and return metrics like FCF, ROE (-5.33%), and ROA (0.68%) suggest the company is not currently generating robust returns on capital or substantial free cash flow from its asset base, which is a critical area for monitoring improvement.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HR Overvalued?
Given the company's negative trailing net income (EPS of -$0.04), the primary valuation metric shifts away from the P/E ratio (trailing -24.1x) to the Price-to-Sales (P/S) ratio, which stands at 5.02x. Compared to industry averages, specific sector multiples are not provided in the data, but the EV/Sales ratio of 9.88x and EV/EBITDA of 19.33x offer alternative measures; without a direct peer benchmark, it is difficult to definitively label this as a premium or discount, though the elevated sales multiples suggest the market is valuing the company's revenue stream highly despite its lack of profitability. Historical context for the stock's own valuation multiples is unavailable due to missing historical ratios data, preventing an assessment of whether the current P/S of 5.02x is near the top or bottom of its historical range; this lack of historical perspective limits the ability to determine if the stock is priced for optimistic expectations or presents a value opportunity relative to its own past.
PE
-24.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's lack of profitability, with a trailing net margin of -20.84% and negative EPS. While the operating margin is positive at 8.04%, the overall loss, negative ROE of -5.33%, and low ROA of 0.68% indicate the asset-heavy business model is not efficiently generating shareholder returns. The elevated P/S ratio of 5.02x is entirely dependent on future earnings growth materializing from an estimated $1.17B in revenue. A failure to achieve the projected EPS of $0.11 would severely pressure the valuation.
Market & Competitive Risks: The key market risk is valuation compression. Trading near its 52-week high after a 38.83% run-up, the stock has limited analyst coverage to support its narrative, increasing its vulnerability to sentiment shifts. Its beta of 0.827 suggests it is less correlated to the market, but as a REIT, it remains sensitive to interest rate movements which affect both its cost of capital and the relative appeal of its dividend yield (6.53%). Sector rotation away from defensive real estate could also pose a headwind.
Worst-Case Scenario: The worst-case scenario involves a double-whammy of failed profitability and sector derating. If upcoming results disappoint and the anticipated EPS turnaround fails, investor confidence would collapse, leading to simultaneous earnings multiple expansion (from negative to positive is a high hurdle) and sales multiple contraction. This could trigger a rapid decline towards the 52-week low of $14.69, representing a potential loss of approximately -29% from the current price of $20.70. The high short ratio of 3.31 indicates a cohort of investors is already positioned for such a downturn.
FAQ
The key risks are: 1) Profitability Risk: The company is not currently profitable (net margin -20.84%), and the anticipated turnaround may fail. 2) Valuation Risk: The P/S of 5.02x is high for an unprofitable company and could compress sharply. 3) Coverage & Liquidity Risk: With only one analyst, the stock suffers from poor price discovery and could be volatile. 4) Interest Rate Risk: As a REIT, its cost of capital and attractiveness versus bonds are sensitive to rising rates. The profitability risk is the most severe, as it directly challenges the investment thesis.
The 12-month forecast presents three scenarios. The Bull Case (25% probability) targets $22-24, requiring successful profitability execution. The Base Case (60% probability) targets $19.50-21.50, involving range-bound consolidation as progress is made. The Bear Case (15% probability) targets $14.70-17.00, triggered by a failed turnaround and sector derating. The Base Case is most likely, implying limited near-term upside from the current ~$20.70 price as the stock digests its prior gains. The key assumption is that the company makes incremental, but not spectacular, progress toward positive earnings.
Based on traditional earnings metrics, HR appears overvalued, with a negative trailing P/E of -24.1x. Using sales-based metrics due to the lack of profits, the P/S ratio of 5.02x and EV/Sales of 9.88x seem elevated, though a direct peer comparison is unavailable. The market is clearly valuing the company's ~$1.17B revenue stream and future earnings potential at a premium. The valuation implies the market expects a swift and successful transition to profitability, as forecasted by the single analyst's $0.11 EPS estimate. Until that is achieved, the stock carries valuation risk.
HR is a speculative buy only for investors comfortable with significant fundamental risk. The stock has had a tremendous run, up 38.83% in the past year, and now trades near its all-time high, pricing in a successful profitability turnaround that is not yet proven. The 6.53% dividend yield is attractive, but the negative EPS and ROE are red flags. It could be a good buy for a patient, sector-focused investor who believes in the outpatient healthcare real estate thesis and is willing to wait for earnings to materialize, but it is not a good buy for conservative investors seeking stable income or proven value.
HR is more suitable for a medium- to long-term investment horizon of 2-3 years. The short-term outlook is clouded by its position near all-time highs and the need to prove its profitability thesis, which will take several quarters. Its low beta of 0.827 suggests it is not a high-volatility trading vehicle for short-term speculation. The long-term story depends on the durability of healthcare real estate demand and the company's ability to generate sustainable funds from operations (FFO). Investors should be prepared to hold through potential volatility while the fundamental story unfolds.